PF-Atlas › Clinical Trials › NCT04783675

Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Rituximab · Phase 2

Registry ID
NCT04783675
Phase
Phase 2
Status
Completed
Drug / intervention
Rituximab
Sponsor
Children's Hospital of Fudan University
Start
2021-04-13
Enrollment
44
Locations
8

About this trial

The main objective is to demonstrate, from the initial episode of nephrotic syndrome (NS) in children with standard prednisolone treatment, once complete remission has occurred, that the use of Rituximab (a single intravenous infusion of 375 mg/m2) may reduce the risk of subsequent relapse during 12-month of follow-up.

View NCT04783675 on ClinicalTrials.gov →

Explore related

All Rituximab trialsAll IPF trials

Related trials

Rituximab — NCT01086540Rituximab — NCT01862926Rituximab — NCT02990286Rituximab — NCT05596786Rituximab — NCT03069248Rituximab — NCT01969409
Medical disclaimer. This page summarizes public trial data for NCT04783675 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.